Klin Farmakol Farm. 2007;21(1):32-35

NOVEL THERAPEUTIC MODALITIES FOR PULMONARY ARTERIAL HYPERTENSION

Iveta ©imková1, MUDr. Pavel Jansa2
1 Katedra kardiológie a angiológie FZ©© SZU, Kardiologická klinika NÚSCH, Bratislava
2 Centrum pro plicní hypertenzi, II. interní klinika kardiologie a angiologie, VFN a 1. LF UK, Praha

Pulmonary arterial hypertension (PAH) covers a wide spectrum of diseases, characteristic by progressive course, very poor life quality and prognosis quod vitam. Major advances in understanding of the mechanism of the disease development, in the diagnostic process opened new horizons of therapeutic effects. Specific therapy of PAH (prostanoids, endothelin receptor antagonists, phosphodiesterase inhibitors) is pharmacologic treatment, acting through pathogenic pathways and therefore changes therapeutic strategy, effectively improves clinical course and prolongs life. From the pharmacoeconomic point of view this therapy is categorized to the finances-consuming drugs.

Keywords: pulmonary arterial hypertension, specific therapy

Published: January 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©imková I, Jansa P. NOVEL THERAPEUTIC MODALITIES FOR PULMONARY ARTERIAL HYPERTENSION. Klin Farmakol Farm. 2007;21(1):32-35.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Simmoneau G, Gali? N, Rubin LJ, Langleben D, Seegner W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, Rich S, Fishman A. Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol 2004; 43, Suppl S: 5S-12S. Go to original source... Go to PubMed...
    2. The Task Force Guidelines on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25: 2243-2278.
    3. Jansa P, Ascherman M, Riedel M, Pafko P, Suza Z. Doporučení pro diagnostiku a léčbu plícní arteriální hypertenze v ČR. Cor Vasa 2004; 46: K35-44.
    4. ©imková I, Gonsalvesová E, Hájková M, Poprac P. Komentár k, ,Odporúčaniam Európskej kardiologickej spoločnosti pre diagnostiku a liečbu pµúcnej artériovej hypertenzie". Cardiol 2005; 13: 167-69.
    5. Rich S, Kaufmann E, Levy PDS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81. Go to original source... Go to PubMed...
    6. Barst RJ, Rubin LJ, Long WA. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296-301. Go to original source... Go to PubMed...
    7. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482. Go to original source... Go to PubMed...
    8. Vachiéry JL, Naeije R. Treprostinil for pulmonary hypertension. Expert Rev Cardiovasc Ther 2004;2:183-191. Go to original source... Go to PubMed...
    9. Rubin LJ, Mendoza J, Hood M. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990;112: 485-491. Go to original source... Go to PubMed...
    10. Simonneau G, Barst RJ, Galié N. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804. Go to original source... Go to PubMed...
    11. Olschewski H, Simonneau G, Galié N. Inhaled Iloprost in severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329. Go to original source... Go to PubMed...
    12. Channick RN, Sitbon O, Barst RJ Endothelin receptors antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 62S-67S. Go to original source... Go to PubMed...
    13. Badesh DB, Abman SH, Ahearn G, Barst RJ, McCrory DC, Simmoneau G, McLaughlin VV. Medical therapy for pulmonary arterial hypertension. Chest 2004; 126: 35S-62S. Go to original source... Go to PubMed...
    14. Michelakis ED, Tymchak W, Noga M, Webster L, Wu XC, Lien D. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 2003;108:2066-2069. Go to original source... Go to PubMed...
    15. Stiebellehner L, Petkov V, Vonbank K. Long-term treatment with oral sildenafil in addition to i.v. epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123:1293-1295. Go to original source... Go to PubMed...
    16. Jansa P, Lindner J, Aschermann M, Paleček T, ©kvařilová M, Horák J, Bečvář R, Tegzová D, Heller S, Kovařík A, Ambroľ D, Kunstýř J, Linhart A. Zkuąenosti s centralizací nemocných s plicní hypertenzí v České republice. LekObz 2005; 54: 316-322.
    17. ©imková I, Pacák J, Vulev I, Jansa P, Aschermann M, Lang I, KlepetkoW. Initial experiences with novel therapy for pulmonary hypertension in Slovakia. Bratisl Lek Listy 2006;107: 239-247. Go to PubMed...
    18. McLaughlin VV, Presberg KV, Doyle LR, Abman SH, Frotin T, Ahearn G. Prognosis of pulmonary arterial hypertension. Chest 2004; 126: 78S-92S. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.